LENZ Therapeutics

LENZ

Market cap $1.16B

VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia for up to 10 hours, a condition impacting approximately 128 million adults in the United States SAN DIEGO, Calif. , Sept. 30, 2025 /PRNewswire/ -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), today announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available.

VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia for up to 10 hours, a condition impacting approximately 128 million adults in the United States SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), today announced VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, is now available.

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Therapeutics, Inc. Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:00 AM EDT Company Participants Evert Schimmelpennink - President, CEO, Secretary & Director Presentation Unknown Analyst All right. Good morning, everyone.

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Therapeutics, Inc. Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Evert Schimmelpennink - President, CEO, Secretary & Director Conference Call Participants Yigal Nochomovitz - Citigroup Inc., Research Division Presentation Yigal Nochomovitz Director and SMid Cap Biotech Analyst So again, welcome, everyone, to Citi's Back to School Biopharma Conference in Boston. It's day 2.

SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor and medical conferences, including presentations featuring VIZZ at Academy 2025 presented by the American Academy of Optometry. Citi's 2025 BioPharma Back to School Conference Date: September 2-3, 2025 Location: Boston, MA Format: Fireside chat at 9:45am EDT (live audio webcast) and 1x1 investor meetings Cantor Global Healthcare Conference Date: September 4, 2025 Location: New York City, NY Format: Fireside chat at 1:35pm EDT (live audio webcast) and 1x1 investor meetings H.C.

VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States

Lenz (LENZ) Q2 Revenue Jumps 604%

LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to a loss of $0.4 per share a year ago.

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval Executed multiple international license and commercialization agreements for LNZ100 including over $195 million in upfront and milestone payments together with double-digit royalties on net sales Cash, cash equivalents and marketable securities of $209.6 million as of June 30, 2025 SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today reported financial results for the second quarter ended June 30, 2025, and recent corporate highlights. “As our PDUFA target action date is rapidly approaching, we are encouraged by our ongoing engagement with the FDA and are confident that the review of our NDA for LNZ100 is on track,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics.

LNZ100 shows superior efficacy and safety in presbyopia treatment, with a strong probability of FDA approval by August 2025. LNZ100 outperforms competitors Vuity and Qlosi, offering faster and greater near-vision improvement with a similar safety profile. Financials are solid with $185M cash, and peak sales could reach $500M, supporting a Buy rating despite some market premium.